Quick Takeaways
- GPCR - Structure Therapeutics Inc. has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: -$5,022,625.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 19 Insiders of Structure Therapeutics Inc.
- Symbol
- GPCR on Nasdaq
- Location
- South San Francisco, CA
What Changed
- Buy value: ; sell value: $5,022,625.
- Net share flow: -96,118.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$5,022,625.
Buys
$0
Shares: 0
Insiders: 0
Sells
$5,022,625
Shares: 96,118
Insiders: 1
Net
-$5,022,625
Shares: -96,118
Insiders: -1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 17,452 | $0 | $961,082 | -$961,082 |
| 3-6 | 0 | 52,356 | $0 | $3,591,384 | -$3,591,384 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 26,310 | $0 | $470,160 | -$470,160 |
Structure Therapeutics Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ph.D. Raymond C. Stevens | CHIEF EXECUTIVE OFFICER, Director | $217,700,989 | Mixed | 19 Mar 2026 | ||
| Jun Yoon | Chief Financial Officer | $216,491,068 | Mixed | 19 Mar 2026 | ||
| FMR LLC | Other*, 10%+ Owner | $46,455,733 | -$5,022,625 | -9.8% | Mixed | 14 Apr 2026 |
| Crespo Blas Coll | Chief Medical Officer | $20,585,311 | Mixed | 19 Mar 2026 | ||
| Ramy Farid | Director | $17,176,500 | Mixed | 07 Feb 2023 | ||
| Xichen Lin | Chief Scientific Officer | $16,762,161 | Mixed | 19 Mar 2026 | ||
| Ashley Hall | Chief Development Officer | $11,361,240 | Mixed | 19 Mar 2026 | ||
| Yingli Ma | Chief Technology Officer | $10,243,323 | Mixed | 19 Mar 2026 | ||
| Matthew Lang | Coo & Gc | $8,898,394 | Median | 15 Apr 2026 | ||
| Mark Allen Bach | Chief Medical Officer | $520,855 | Mixed | 15 Mar 2024 | ||
| Melita Sun Jung | Chief Business Officer | $62,460 | Mixed | 07 Feb 2023 | ||
| Joanne Waldstreicher | Director | Mixed | 23 Jun 2025 | |||
| Sharon Tetlow | Director | Mixed | 23 Jun 2025 | |||
| Eric Dobmeier | Director | Mixed | 23 Jun 2025 | |||
| BVF PARTNERS L P/IL | 10%+ Owner | Mixed | 10 May 2023 | |||
| Daniel G. Welch | Director | Mixed | 23 Jun 2025 | |||
| Angus C. Russell | Director | Mixed | 23 Jun 2025 | |||
| Ted W. Love | Director | Mixed | 23 Jun 2025 | |||
| FIL Ltd | Other* | Mixed | 07 Feb 2023 |
Top shareholders of Structure Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13D/G
3/4/5
13F
|
Other*, 10%+ Owner · Company |
15%
|
31,112,634
|
$2,163,883,695 | +$776,609,280 | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
|
Company |
10%
|
21,365,952
|
$1,481,942,431 | +$50,941,729 | 31 Dec 2025 | |
| Deep Track Capital, LP |
13D/G
13F
|
Company |
6%
|
12,335,346
|
$855,579,599 | -$21,646,354 | 31 Dec 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
4.9%
|
10,437,066
|
$723,914,898 | +$57,243,848 | 31 Dec 2025 | |
| Avoro Capital Advisors LLC |
13D/G
13F
|
Company |
9.4%
|
16,216,665
|
$454,066,620 | $0 | 30 Sep 2025 | |
| Ph.D. Raymond C. Stevens |
3/4/5
|
CHIEF EXECUTIVE OFFICER, Director |
—
mixed-class rows
|
3,284,233
mixed-class rows
|
$217,700,989 | — | 19 Mar 2026 | |
| Jun Yoon |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
3,088,080
mixed-class rows
|
$216,491,068 | — | 19 Mar 2026 | |
| Capital Research Global Investors |
13D/G
|
— |
3.8%
|
6,492,435
|
$168,218,991 | $0 | 31 Mar 2025 | |
| BVF INC/IL |
13F
|
Company |
1.6%
|
3,459,358
|
$166,741,056 | — | 31 Mar 2026 | |
| JANUS HENDERSON GROUP PLC |
13D/G
13F
|
Company |
7.7%
|
4,448,826
|
$124,567,128 | -$3,477,040 | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.1%
|
2,305,457
|
$111,123,045 | — | 31 Mar 2026 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.94%
|
2,000,696
|
$96,434,000 | — | 31 Mar 2026 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.82%
|
1,753,764
|
$84,531,425 | — | 31 Mar 2026 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.74%
|
1,577,356
|
$76,028,559 | — | 31 Mar 2026 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.69%
|
1,475,403
|
$71,114,425 | — | 31 Mar 2026 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.68%
|
1,438,031
|
$69,313,416 | — | 31 Mar 2026 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.67%
|
1,432,529
|
$69,047,898 | — | 31 Mar 2026 | |
| Siren, L.L.C. |
13F
|
Individual |
0.62%
|
1,328,698
|
$64,043,244 | — | 31 Mar 2026 | |
| Casdin Capital, LLC |
13F
|
Company |
0.55%
|
1,175,000
|
$56,635,000 | — | 31 Mar 2026 | |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC |
13F
|
Company |
0.54%
|
1,151,300
|
$55,492,660 | — | 31 Mar 2026 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.3%
|
638,813
|
$44,429,444 | — | 31 Mar 2026 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.36%
|
767,993
|
$37,017,263 | — | 31 Mar 2026 | |
| PACIFIC HEIGHTS ASSET MANAGEMENT LLC |
13F
|
Company |
0.35%
|
750,000
|
$36,150,000 | — | 31 Mar 2026 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.3%
|
640,217
|
$30,858,459 | — | 31 Mar 2026 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
0.26%
|
545,287
|
$26,282,833 | — | 31 Mar 2026 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.25%
|
531,595
|
$25,622,876 | — | 31 Mar 2026 | |
| Logos Global Management LP |
13F
|
Company |
0.23%
|
500,000
|
$24,100,000 | — | 31 Mar 2026 | |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND |
13F
|
Company |
0.22%
|
467,800
|
$22,547,960 | — | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
|
Company |
0.21%
|
441,975
|
$21,303,196 | — | 31 Mar 2026 | |
| Crespo Blas Coll |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
376,019
mixed-class rows
|
$20,585,311 | — | 19 Mar 2026 | |
| Aberdeen Group plc |
13F
|
Company |
0.18%
|
391,809
|
$18,885,194 | — | 31 Mar 2026 | |
| Ramy Farid |
3/4/5
|
Director |
—
mixed-class rows
|
3,535,495
mixed-class rows
|
$17,176,500 | — | 07 Feb 2023 | |
| Xichen Lin |
3/4/5
|
CHIEF SCIENTIFIC OFFICER |
—
mixed-class rows
|
282,663
mixed-class rows
|
$16,762,161 | — | 19 Mar 2026 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.16%
|
331,867
|
$15,995,989 | — | 31 Mar 2026 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.14%
|
305,400
|
$14,720,280 | — | 31 Mar 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.14%
|
304,934
|
$14,697,819 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.12%
|
260,543
|
$12,558,172 | — | 31 Mar 2026 | |
| Catalio Capital Management, LP |
13F
|
Company |
0.12%
|
255,379
|
$12,309,268 | — | 31 Mar 2026 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
254,969
|
$12,289,506 | — | 31 Mar 2026 | |
| SEB Asset Management AB |
13F
|
Company |
0.12%
|
245,043
|
$11,811,058 | — | 31 Mar 2026 | |
| Pentwater Capital Management LP |
13F
|
Company |
0.12%
|
245,000
|
$11,809,000 | — | 31 Mar 2026 | |
| Ashley Hall |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
214,722
mixed-class rows
|
$11,361,240 | — | 19 Mar 2026 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.11%
|
232,093
|
$11,186,883 | — | 31 Mar 2026 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.1%
|
219,516
|
$10,580,671 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.1%
|
212,919
|
$10,262,695 | — | 31 Mar 2026 | |
| Yingli Ma |
3/4/5
|
CHIEF TECHNOLOGY OFFICER |
—
mixed-class rows
|
180,195
mixed-class rows
|
$10,243,323 | — | 19 Mar 2026 | |
| Sio Capital Management, LLC |
13F
|
Company |
0.1%
|
209,093
|
$10,078,283 | — | 31 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.1%
|
204,790
|
$9,870,878 | — | 31 Mar 2026 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.1%
|
204,762
|
$9,869,528 | — | 31 Mar 2026 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.09%
|
200,267
|
$9,652,869 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Structure Therapeutics Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Matthew Lang | GPCR | Ordinary Shares | Award | 184,614 | 184,614 | 15 Apr 2026 | Direct | |||
| Matthew Lang | GPCR | Share option (right to buy) | Award | 223,776 | 223,776 | 15 Apr 2026 | Direct | |||
| Fmr Llc | GPCR | American Depositary Shares | Sale | -33.3% | $885,801 | $55.07 | -16,085 | 32,171 | 14 Apr 2026 | F-Prime Capital Partners Life Sciences Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -33.3% | $75,281 | $55.07 | -1,367 | 2,736 | 14 Apr 2026 | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Ashley Hall | GPCR | Ordinary Shares | Award | 44.4% | 47,706 | 155,187 | 19 Mar 2026 | Direct | ||
| Ashley Hall | GPCR | Employee Stock Option (right to buy) | Award | 59,073 | 59,073 | 19 Mar 2026 | Direct | |||
| Crespo Blas Coll | GPCR | Ordinary Shares | Award | 37% | 75,897 | 280,878 | 19 Mar 2026 | Direct | ||
| Crespo Blas Coll | GPCR | Employee Stock Option (right to buy) | Award | 93,984 | 93,984 | 19 Mar 2026 | Direct | |||
| Yingli Ma | GPCR | Ordinary Shares | Award | 30.3% | 32,526 | 139,917 | 19 Mar 2026 | Direct | ||
| Yingli Ma | GPCR | Employee Stock Option (right to buy) | Award | 40,278 | 40,278 | 19 Mar 2026 | Direct | |||
| Xichen Lin | GPCR | Ordinary Shares | Award | 23.4% | 43,368 | 228,960 | 19 Mar 2026 | Direct | ||
| Xichen Lin | GPCR | Employee Stock Option (right to buy) | Award | 53,703 | 53,703 | 19 Mar 2026 | Direct | |||
| Jun Yoon | GPCR | Ordinary Shares | Award | 8.02% | 104,085 | 1,401,656 | 19 Mar 2026 | Direct | ||
| Jun Yoon | GPCR | Employee Stock Option (right to buy) | Award | 128,892 | 128,892 | 19 Mar 2026 | Direct | |||
| Raymond C. Stevens | GPCR | Ordinary Shares | Award | 22.8% | 260,217 | 1,401,593 | 19 Mar 2026 | Direct | ||
| Raymond C. Stevens | GPCR | Employee Stock Option (right to buy) | Award | 322,230 | 322,230 | 19 Mar 2026 | Direct | |||
| Crespo Blas Coll | GPCR | Ordinary Shares | Tax liability | -5.45% | -11,826 | 204,981 | 03 Mar 2026 | Direct | ||
| Yingli Ma | GPCR | Ordinary Shares | Tax liability | -9.53% | -11,313 | 107,391 | 03 Mar 2026 | Direct | ||
| Xichen Lin | GPCR | Ordinary Shares | Tax liability | -9.17% | -18,735 | 185,592 | 03 Mar 2026 | Direct | ||
| Jun Yoon | GPCR | Ordinary Shares | Tax liability | -1.69% | -22,305 | 1,297,571 | 03 Mar 2026 | Direct | ||
| Ashley Hall | GPCR | Ordinary Shares | Tax liability | -4.31% | -4,836 | 107,481 | 03 Mar 2026 | Direct | ||
| Raymond C. Stevens | GPCR | Ordinary Shares | Tax liability | -4.47% | -53,454 | 1,141,376 | 03 Mar 2026 | Direct | ||
| Fmr Llc | GPCR | American Depositary Shares | Sale | -18% | $890,219 | $83.92 | -10,608 | 48,256 | 15 Jan 2026 | F-Prime Capital Partners Life Sciences Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -8.51% | $449,662 | $82.10 | -5,477 | 58,864 | 15 Jan 2026 | F-Prime Capital Partners Life Sciences Fund VI LP LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -25% | $113,872 | $83.30 | -1,367 | 4,103 | 15 Jan 2026 | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -100% | $1,970,192 | $61.24 | -32,170 | 0 | 08 Dec 2025 | F-Prime Capital Partners Life Sciences Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -33.3% | -16,085 | 32,170 | 08 Dec 2025 | F-Prime Capital Partners Life Sciences Fund VI LP | ||
| Fmr Llc | GPCR | American Depositary Shares | Sale | -100% | $167,439 | $61.24 | -2,734 | 1 | 08 Dec 2025 | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Fmr Llc | GPCR | American Depositary Shares | Sale | -33.3% | -1,367 | 2,735 | 08 Dec 2025 | F-Prime Capital Partners Life Sciences Advisors Fund VI LP | ||
| Ashley Hall | GPCR | American Depositary Shares | Award | 105.3% | 237 | 462 | 20 Nov 2025 | Direct | ||
| Raymond C. Stevens | GPCR | American Depositary Shares | Award | 82.4% | 824 | 1,824 | 20 Nov 2025 | Direct | ||
| Ashley Hall | GPCR | Ordinary Shares | Tax liability | -5.09% | -6,021 | 112,317 | 18 Sep 2025 | Direct | ||
| Crespo Blas Coll | GPCR | Ordinary Shares | Tax liability | -3.6% | -8,106 | 216,807 | 18 Sep 2025 | Direct | ||
| Fmr Llc | GPCR | American Depositary Shares | Sale | -1.71% | $470,160 | $17.87 | -26,310 | 1,515,558 | 30 Jul 2025 | Shares held by persons and entities whose shares are subject to reporting by the undersigned |
| Yingli Ma | GPCR | Ordinary Shares | Tax liability | -3.63% | -4,470 | 118,704 | 01 Jul 2025 | Direct | ||
| Xichen Lin | GPCR | Ordinary Shares | Tax liability | -5.92% | -12,846 | 204,327 | 01 Jul 2025 | Direct | ||
| Crespo Blas Coll | GPCR | Ordinary Shares | Tax liability | -0.63% | -1,434 | 224,913 | 01 Jul 2025 | Direct | ||
| Crespo Blas Coll | GPCR | Ordinary Shares | Award | 3.66% | 7,992 | 226,347 | 01 Jul 2025 | Direct | ||
| Yingli Ma | GPCR | Ordinary Shares | Award | 24.8% | 24,459 | 123,174 | 01 Jul 2025 | Direct | ||
| Xichen Lin | GPCR | Ordinary Shares | Award | 35.6% | 57,078 | 217,173 | 01 Jul 2025 | Direct | ||
| Jun Yoon | GPCR | Ordinary Shares | Tax liability | -0.53% | -7,089 | 1,319,876 | 01 Jul 2025 | Direct | ||
| Jun Yoon | GPCR | Ordinary Shares | Award | 3.08% | 39,606 | 1,326,965 | 01 Jul 2025 | Direct | ||
| Raymond C. Stevens | GPCR | Ordinary Shares | Tax liability | -1.33% | -16,050 | 1,194,830 | 01 Jul 2025 | Direct | ||
| Raymond C. Stevens | GPCR | Ordinary Shares | Award | 8% | 89,697 | 1,210,880 | 01 Jul 2025 | Direct | ||
| Angus C. Russell | GPCR | Share Option (right to buy) | Award | 42,833 | 42,833 | 23 Jun 2025 | Direct | |||
| Ted W. Love | GPCR | Share Option (right to buy) | Award | 51,804 | 51,804 | 23 Jun 2025 | Direct | |||
| Joanne Waldstreicher | GPCR | Share Option (right to buy) | Award | 51,804 | 51,804 | 23 Jun 2025 | Direct | |||
| Eric Dobmeier | GPCR | Share Option (right to buy) | Award | 51,804 | 51,804 | 23 Jun 2025 | Direct | |||
| Sharon Tetlow | GPCR | Share Option (right to buy) | Award | 51,804 | 51,804 | 23 Jun 2025 | Direct | |||
| Daniel G. Welch | GPCR | Share Option (right to buy) | Award | 51,804 | 51,804 | 23 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.